Arch Therapeutics, Inc. (ARTH)
USD 0.23
(31.81%)
USD 0.23
(31.81%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -3.88 Million USD | 11.62% |
| 2022 | -4.7 Million USD | 7.92% |
| 2021 | -6.08 Million USD | -2.54% |
| 2020 | -5.34 Million USD | 26.19% |
| 2019 | -6.36 Million USD | -9.98% |
| 2018 | -7.44 Million USD | -1.96% |
| 2017 | -7.3 Million USD | -20.66% |
| 2016 | - USD | -10.81% |
| 2015 | -5.46 Million USD | -18.41% |
| 2014 | -4.61 Million USD | -164.37% |
| 2013 | -1.74 Million USD | -4664.49% |
| 2012 | -36.61 Thousand USD | -626.84% |
| 2011 | -5037.00 USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -1.49 Million USD | -12.48% |
| 2024 Q2 | -876.18 Thousand USD | 41.35% |
| 2024 Q3 | -1.02 Million USD | -468.65% |
| 2023 Q1 | -1.27 Million USD | 11.48% |
| 2023 Q2 | -1.42 Million USD | -11.77% |
| 2023 FY | - USD | 11.62% |
| 2023 Q3 | -1.01 Million USD | 28.84% |
| 2023 Q4 | -1.32 Million USD | -30.98% |
| 2022 Q2 | -1.75 Million USD | -15.97% |
| 2022 FY | - USD | 7.92% |
| 2022 Q4 | -1.44 Million USD | -43.16% |
| 2022 Q1 | -1.5 Million USD | 12.47% |
| 2022 Q3 | -1 Million USD | 42.51% |
| 2021 Q1 | -1.37 Million USD | -4.48% |
| 2021 Q4 | -1.72 Million USD | -15.79% |
| 2021 FY | - USD | -2.54% |
| 2021 Q2 | -1.74 Million USD | -27.58% |
| 2021 Q3 | -1.48 Million USD | 14.92% |
| 2020 Q3 | -1.57 Million USD | -0.11% |
| 2020 Q1 | -1.57 Million USD | 28.9% |
| 2020 Q2 | -1.57 Million USD | 0.12% |
| 2020 Q4 | -1.31 Million USD | 16.77% |
| 2020 FY | - USD | 26.19% |
| 2019 Q3 | -1.85 Million USD | 41.8% |
| 2019 Q4 | -2.21 Million USD | -19.75% |
| 2019 FY | - USD | -9.98% |
| 2019 Q1 | -933.63 Thousand USD | 58.16% |
| 2019 Q2 | -3.18 Million USD | -240.92% |
| 2018 Q2 | -2.01 Million USD | -27.25% |
| 2018 FY | - USD | -1.96% |
| 2018 Q4 | -2.23 Million USD | -37.89% |
| 2018 Q3 | -1.61 Million USD | 19.59% |
| 2018 Q1 | -1.58 Million USD | 15.9% |
| 2017 Q4 | -1.88 Million USD | -2.18% |
| 2017 FY | - USD | -20.66% |
| 2017 Q1 | -1.37 Million USD | 22.87% |
| 2017 Q2 | -2.2 Million USD | -60.18% |
| 2017 Q3 | -1.84 Million USD | 16.47% |
| 2016 Q1 | -1.27 Million USD | 19.86% |
| 2016 FY | - USD | -10.81% |
| 2016 Q4 | -1.78 Million USD | -2.95% |
| 2016 Q3 | -1.73 Million USD | -38.09% |
| 2016 Q2 | -1.25 Million USD | 1.94% |
| 2015 Q2 | -1.25 Million USD | 1.14% |
| 2015 FY | - USD | -18.41% |
| 2015 Q1 | -1.27 Million USD | 8.58% |
| 2015 Q4 | -1.59 Million USD | -19.3% |
| 2015 Q3 | -1.33 Million USD | -6.57% |
| 2014 FY | - USD | -164.37% |
| 2014 Q4 | -1.38 Million USD | -21.23% |
| 2014 Q3 | -1.14 Million USD | 11.55% |
| 2014 Q2 | -1.29 Million USD | -65.96% |
| 2014 Q1 | -780.67 Thousand USD | 18.77% |
| 2013 Q3 | -494.76 Thousand USD | -10783.52% |
| 2013 Q4 | -961.04 Thousand USD | -94.24% |
| 2013 FY | - USD | -4664.49% |
| 2013 Q2 | -4546.00 USD | -259.37% |
| 2013 Q1 | -1265.00 USD | 93.89% |
| 2012 Q2 | -9108.00 USD | -949.31% |
| 2012 Q4 | -20.71 Thousand USD | -250.14% |
| 2012 FY | - USD | -626.84% |
| 2012 Q1 | -868.00 USD | 82.57% |
| 2012 Q3 | -5917.00 USD | 35.04% |
| 2011 Q1 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q3 | -19.00 USD | 0.0% |
| 2011 Q4 | -4981.00 USD | -26115.79% |
| 2011 Q2 | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 94.532% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 34.485% |
| SQZ Biotechnologies Company | -64.14 Million USD | 93.944% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 77.638% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 104.131% |
| Mesoblast Limited | -62.38 Million USD | 93.774% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -152.877% |
| Genus plc | 73.7 Million USD | 105.27% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 41.249% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -9.51% |
| Marizyme, Inc. | -34.28 Million USD | 88.669% |
| ContraFect Corporation | -64.99 Million USD | 94.024% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 55.719% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 14.181% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -177.094% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -46.886% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -67.152% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -649.802% |
| Accustem Sciences Inc. | -3.74 Million USD | -3.681% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 91.946% |
| EV Biologics, Inc. | -1.26 Million USD | -206.544% |
| Q BioMed Inc. | -617.62 Thousand USD | -528.909% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 208.744% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -514.213% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -70.03% |
| Biomind Labs Inc. | -1.03 Million USD | -275.46% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 139.327% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 45.759% |
| Skye Bioscience, Inc. | -13.54 Million USD | 71.328% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -161.146% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -15437.28% |
| IMV Inc. | -35.52 Million USD | 89.065% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 75.524% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -55.251% |
| GB Sciences, Inc. | -1.41 Million USD | -173.566% |
| Alpha Cognition Inc. | -9.7 Million USD | 59.979% |
| HST Global, Inc. | -5303.00 USD | -73147.596% |
| CSL Limited | 4.78 Billion USD | 100.081% |
| Halberd Corporation | -74.27 Thousand USD | -5129.365% |
| Enzolytics Inc. | -2.12 Million USD | -83.047% |
| Resverlogix Corp. | -11.74 Million USD | 66.919% |
| Affymax, Inc. | -14.29 Million USD | 72.827% |
| SYBLEU INC | -141.57 Thousand USD | -2643.726% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -26.814% |
| argenx SE | -216.02 Million USD | 98.202% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 92.981% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 419.172% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -159.144% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 1125.309% |
| AVAX Technologies, Inc. | -6.11 Million USD | 36.454% |
| Zenith Capital Corp. | -8.6 Million USD | 54.865% |
| Genscript Biotech Corporation | -248.71 Million USD | 98.438% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -22196.768% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -58.773% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -2106.695% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 90.2% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -34.297% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -271.239% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 57867.995% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -121.961% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -102.212% |
| BioStem Technologies, Inc. | -7.55 Million USD | 48.577% |
| ONE Bio Corp. | 13.61 Million USD | 128.534% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -2044.99% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -88.834% |
| Agentix Corp. | -1.37 Million USD | -183.164% |
| LadRx Corporation | 412.28 Thousand USD | 1042.149% |
| Cell Source, Inc. | -4.27 Million USD | 9.086% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -957.761% |
| Regen BioPharma, Inc. | 1.46 Million USD | 364.968% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -314.571% |
| NovAccess Global Inc. | -1.03 Million USD | -275.37% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 143.872% |
| Itoco Inc. | -1.86 Million USD | -107.829% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -923.213% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -248.057% |
| Kadimastem Ltd | -2.62 Million USD | -48.009% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -1524.219% |
| CytoDyn Inc. | -18.02 Million USD | 78.455% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -4815.056% |
| Mobile Lads Corp. | -2.24 Million USD | -73.317% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -31663.186% |
| Qrons Inc. | -40.08 Thousand USD | -9591.175% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -699.773% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 836.458% |
| Rebus Holdings, Inc. | -951 Thousand USD | -308.446% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -265.752% |
| International Stem Cell Corporation | 202 Thousand USD | 2022.931% |
| Bioxytran, Inc. | -3.82 Million USD | -1.68% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -7279.027% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -57.775% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 89.171% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -8531.822% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -41.867% |
| Neutra Corp. | -181.24 Thousand USD | -2043.109% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 80.732% |
| PureTech Health plc | -11.62 Million USD | 66.592% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 80.73% |
| IXICO plc | -707 Thousand USD | -449.409% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 49.456% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 91.966% |
| CSL Limited | 4.73 Billion USD | 100.082% |
| Cellectis S.A. | -92.63 Million USD | 95.807% |